Case report shows resolution of chronic GVHD in young adult, suggesting new treatment path.
Steroid‐refractory chronic cutaneous graft‐versus‐host disease (GVHD) causes substantial morbidity, prolonged hospitalization, and non‐relapse mortality after allogeneic hematopoietic cell transplantation. We report a young adult with multisystem chronic GVHD and recurrent life‐threatening inflammatory skin flares refractory to multiple standard therapies, with cumulative inpatient care exceeding 1 year. Under an institutional review board‐approved compassionate‐use protocol, he received a non‐cytotoxic monoclonal antibody targeting CD162 (P‐selectin glycoprotein ligand‐1). Treatment was associated with durable resolution of active cutaneous GVHD, corticosteroid reduction, improved mobility, and meaningful recovery in daily function and quality of life. Trial Registration The author has confirmed clinical trial registration is not needed for this submission.
No takes yet. Share an insight, caveat, or question.
Lieberman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: